Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Molecules ; 25(4)2020 Feb 12.
Artículo en Inglés | MEDLINE | ID: mdl-32059436

RESUMEN

Oral administration of bovine collagen peptide (CP) combined with calcium citrate (CC) has been found to inhibit bone loss in ovariectomized rats. However, the protective effects of CP and CP-CC against bone loss have not been investigated in a tail-suspension simulated microgravity (SMG) rat model. Adult Sprague-Dawley rats (n = 40) were randomly divided into five groups (n = 8): a control group with normal gravity, a SMG control group, and three SMG groups that underwent once-daily gastric gavage with CP (750 mg/kg body weight), CC (75 mg/kg body weight) or CP-CC (750 and 75 mg/kg body weight, respectively) for 28 days. After sacrifice, the femurs were analyzed by dual-energy X-ray absorptiometry, three-point bending mechanical tests, microcomputed tomography, and serum bone metabolic markers. Neither CP nor CP-CC treatment significantly inhibited bone loss in SMG rats, as assessed by dual-energy X-ray absorptiometry and three-point bending mechanical tests. However, both CP and CP-CC treatment were associated with partial prevention of the hind limb unloading-induced deterioration of bone microarchitecture, as demonstrated by improvements in trabecular number and trabecular separation. CP-CC treatment increased serum osteocalcin levels. Dietary supplementation with CP or CP-CC may represent an adjunct strategy to reduce the risk of fracture in astronauts.


Asunto(s)
Enfermedades Óseas Metabólicas/tratamiento farmacológico , Citrato de Calcio/farmacología , Colágeno/farmacología , Péptidos/farmacología , Animales , Densidad Ósea/efectos de los fármacos , Enfermedades Óseas Metabólicas/diagnóstico por imagen , Enfermedades Óseas Metabólicas/metabolismo , Enfermedades Óseas Metabólicas/patología , Bovinos , Colágeno/química , Fémur/diagnóstico por imagen , Fémur/efectos de los fármacos , Fémur/patología , Suspensión Trasera/métodos , Humanos , Ovariectomía , Péptidos/química , Ratas , Ratas Sprague-Dawley , Cola (estructura animal)/diagnóstico por imagen , Cola (estructura animal)/efectos de los fármacos , Cola (estructura animal)/fisiopatología , Microtomografía por Rayos X
2.
Ethiop J Health Sci ; 25(2): 139-46, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26124621

RESUMEN

BACKGROUND: Ocimum suave willd is one of the plants traditionally used for the treatment of inflammation and related disorders in different parts of Ethiopia. The aim of the current study was to evaluate the analgesic and antipyretic activities of the solvent fractions (n-butanol and water) of O. suave aqueous leaves extract. MATERIALS AND METHODS: Acetic acid writhing and tail flick tests were used to evaluate the analgesic activity, and yeast-induced fever in mice was used to evaluate the antipyretic activity of the solvent fractions. RESULTS: Both solvent fractions exhibited inhibitory effect against acetic acid induced writhing at all tested dose levels in a dose dependent manner. The water fraction inhibited writhing by 47.69% at a dose of 200 mg/kg which was comparable to that by ASA, the standard drug. In the tail flick test, 200 mg/kg dose of both solvent fractions showed significant activity (P<0.05) after 0.5h, 1h and 3hrs of their administration. Both n- butanol and water fractions produced significant reduction in yeast induced fever at all doses employed. CONCLUSION: From these findings, it can be concluded that the n-butanol and water fractions of O. suave aqueous leaves extract have potential analgesic and antipyretic activity in mice.


Asunto(s)
Analgésicos/farmacología , Antipiréticos/farmacología , Fiebre/tratamiento farmacológico , Ocimum/química , Extractos Vegetales/farmacología , Hojas de la Planta/química , 1-Butanol , Ácido Acético , Analgésicos/aislamiento & purificación , Animales , Antipiréticos/aislamiento & purificación , Relación Dosis-Respuesta a Droga , Etiopía , Fiebre/inducido químicamente , Inflamación/tratamiento farmacológico , Ratones , Fitoterapia/métodos , Extractos Vegetales/química , Cola (estructura animal)/efectos de los fármacos , Cola (estructura animal)/fisiopatología , Agua , Levaduras
3.
J Pain ; 12(1): 51-60, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20554480

RESUMEN

UNLABELLED: We evaluated the effectiveness of intrathecal antagonists of α1- (WB4101) and α2- (idazoxan) adrenoceptors and serotonergic (methysergide), opioid (naloxone), muscarinic (atropine), GABA(A) (bicuculline) and GABA(B) (phaclofen) receptors in blocking 2- or 100-Hz electroacupuncture (EA)-induced analgesia (EAIA) in the rat tail-flick test. EA was applied bilaterally to the Zusanli and Sanyinjiao acupoints in lightly anesthetized rats. EA increased tail-flick latency, where the effect of 2-Hz EA lasted longer than that produced by 100-Hz EA. The 2-Hz EAIA was inhibited by naloxone or atropine, was less intense and shorter after WB4101 or idazoxan, and was shorter after methysergide, bicuculline, or phaclofen. The 100-Hz EAIA was less intense and shorter after naloxone and atropine, less intense and longer after phaclofen, shorter after methysergide or bicuculline, and remained unchanged after WB4101 or idazoxan. We postulate that the intensity of the effect of 2-Hz EA depends on noradrenergic descending mechanisms and involves spinal opioid and muscarinic mechanisms, whereas the duration of the effect depends on both noradrenergic and serotonergic descending mechanisms, and involves spinal GABAergic modulation. In contrast, the intensity of 100-Hz EAIA involves spinal muscarinic, opioid, and GABA(B) mechanisms, while the duration of the effects depends on spinal serotonergic, muscarinic, opioid, and GABA(A) mechanisms. PERSPECTIVE: The results of this study indicate that 2- and 100-Hz EA induce analgesia in the rat tail-flick test activating different descending mechanisms at the spinal cord level that control the intensity and duration of the effect. The adequate pharmacological manipulation of such mechanisms may improve EA effectiveness for pain management.


Asunto(s)
Analgesia/métodos , Anestésicos Intravenosos/uso terapéutico , Electroacupuntura/métodos , Manejo del Dolor , Cola (estructura animal)/fisiopatología , Adyuvantes Anestésicos/farmacología , Antagonistas Adrenérgicos alfa/farmacología , Animales , Atropina/farmacología , Baclofeno/análogos & derivados , Baclofeno/farmacología , Bicuculina/farmacología , Biofisica , Dioxanos/farmacología , Modelos Animales de Enfermedad , GABAérgicos/farmacología , Masculino , Metisergida/farmacología , Modelos Biológicos , Análisis Multivariante , Naloxona/farmacología , Antagonistas de Narcóticos/farmacología , Dolor/fisiopatología , Dimensión del Dolor/métodos , Ratas , Ratas Wistar , Tiempo de Reacción/efectos de los fármacos , Antagonistas de la Serotonina/farmacología , Tiopental/uso terapéutico , Factores de Tiempo
4.
Proc Inst Mech Eng H ; 222(2): 241-8, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18441759

RESUMEN

Electroacupuncture (EA) has long been used as conservative treatment for low back pain (LBP). Its effect on relief of back pain has been demonstrated in many clinical studies. However, whether it has any effect on the biological properties of an intervertebral disc, which is one of the major causes of LBP, is still unclear. The aim of this study was, therefore, to investigate the effects of EA with different simulation frequencies on an intervertebral disc with simulated degeneration using an in-vivo rat-tail model. In this study, 33 rats were used. Disc degeneration was simulated in the rat caudal 8-9 disc via continuous static compressive loading of 11 N for 2 weeks. EA with a frequency of 2 or 100 Hz was then applied to the degenerated disc for 3 weeks with 3 sessions/week and 20 min/session. The intervertebral disc height was measured before and after compression as well as after EA intervention for 3 weeks. The static compression was found to result in a reduction in the disc height of about 22 per cent. There was no evidence that this change could be reversed after resting or the EA intervention. However, EA at 100 Hz was found to induce a further decrease in disc height, which was not shown for the rats after resting or EA at 2 Hz. The results of this study showed that effects of EA on disc degeneration are frequency dependent and adverse effects could result if EA at a certain frequency was used.


Asunto(s)
Modelos Animales de Enfermedad , Electroacupuntura/métodos , Desplazamiento del Disco Intervertebral/fisiopatología , Desplazamiento del Disco Intervertebral/terapia , Inestabilidad de la Articulación/fisiopatología , Animales , Humanos , Desplazamiento del Disco Intervertebral/diagnóstico , Inestabilidad de la Articulación/diagnóstico , Masculino , Ratas , Ratas Sprague-Dawley , Cola (estructura animal)/fisiopatología , Resultado del Tratamiento
5.
Drug Deliv ; 12(3): 133-9, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16025842

RESUMEN

Ketorolac tromethamine has to be given every 6 hr intramuscularly in patients for acute pain, so to avoid frequent dosing and patient inconvenience we found it to be a suitable candidate for parenteral controlled delivery by biodegradable microspheres for the present study. Ketorolac tromethamine-loaded microspheres were prepared by o/w emulsion solvent evaporation technique using different polymers: polycaprolactone, poly lactic-co-glycolic acid (PLGA 65/35), and poly lactic-co-glycolic acid (PLGA 85/15). To tailor the release profile of drug for several days, blends of PLGA 65/35 and PLGA 85/15 were prepared with polycaprolactone (PCL) in different ratios. The results revealed that microspheres made with 1:3 (PLGA65/35:PCL) blend released 97% of the drug in 5 days as compared 97% in 30 days in with pure PLGA65/35 microspheres. Microspheres made with 1:1 (PLGA65/35:PCL) and 3:1 (PLGA65/35:PCL released 98% of the drug in 30 days. In microspheres made with 1:3 (PLGA85/15:PCL), almost the entire drug was released in a week whereas in batches made with pure PLGA85/15 and 3:1 (PLGA 85/15:PCL) more than 80% of the drug was released in 60 days as compared with 96% in 60 days in 1:1 (PLGA85/15:PCL). Higher encapsulation efficiency was obtained with microspheres made with pure PLGA 65/35. These formulations were characterized for particle size analysis by Malvern mastersizer that revealed particle size in range of 12-15 micron and 12-22 micron for microspheres made with polymer blends of PLGA 65/35:PCL and PLGA85/15:PCL, respectively. In pure PLGA65/35 and PLGA85/15, particle size was 28 micron and 8 micron, respectively. Surface topography was studied by scanning electron microscopy that revealed a spherical shape of microspheres. From our study it as concluded that with careful selection of different polymers and their combinations, we can tailor the release of ketorolac tromethamine for long periods.


Asunto(s)
Preparaciones de Acción Retardada/farmacocinética , Ketorolaco Trometamina/farmacocinética , Microesferas , Tecnología Farmacéutica/métodos , Animales , Materiales Biocompatibles/administración & dosificación , Materiales Biocompatibles/química , Materiales Biocompatibles/farmacocinética , Biodegradación Ambiental , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Calor , Concentración de Iones de Hidrógeno , Inyecciones Subcutáneas , Ketorolaco Trometamina/administración & dosificación , Ketorolaco Trometamina/química , Ácido Láctico/química , Ratones , Microscopía Electrónica de Rastreo , Dimensión del Dolor/efectos de los fármacos , Tamaño de la Partícula , Poliésteres/química , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/química , Cola (estructura animal)/fisiopatología , Factores de Tiempo
6.
J Pharmacol Sci ; 97(1): 75-82, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15644592

RESUMEN

I and coauthor previously reported the memory facilitation effect of morphine. The main purpose of this study was to evaluate the involvement of the N-methyl-D-aspartate (NMDA) receptor in associative tolerance to morphine by a contextual procedure. Antinociceptive response latency was measured by the tail-pinch method during repeated morphine (5 mg/kg, s.c.) injection for four consecutive days with pretreatment by dizocilpine (0.01, 0.05, 0.1 mg/kg, i.p.) at 30 min prior to morphine injection in the training phase and before and after morphine injection in the test phase. The nociceptive response latency was shortened by the single administration of dizocilpine (0.05 to 0.25 mg/kg, i.p.). Pretreatment by dizocilpine at 0.05 or 0.1 mg/kg weakened the antinociception to morphine on Day 1, but decreased the tolerance throughout the training phase. In the test phase, the animals were allocated into the same and different contexts. In the test phase, hyperalgesia before morphine injection in the same context and antinociception after morphine injection in the different context were evident in the saline-pretreated group in the training phase, but they were not observed in those contexts in the dizocilpine-pretreated groups. These results suggest that memory dysfunction with dizocilpine inhibits the recovery of associative tolerance to morphine by contextual change.


Asunto(s)
Maleato de Dizocilpina/farmacocinética , Memoria/efectos de los fármacos , Morfina/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Animales , Maleato de Dizocilpina/administración & dosificación , Maleato de Dizocilpina/efectos adversos , Esquema de Medicación , Evaluación Preclínica de Medicamentos/métodos , Tolerancia a Medicamentos/fisiología , Hiperalgesia/fisiopatología , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Masculino , Memoria/fisiología , Ratones , Morfina/administración & dosificación , Morfina/antagonistas & inhibidores , Dolor/tratamiento farmacológico , Dolor/fisiopatología , Umbral del Dolor/psicología , Tiempo de Reacción/efectos de los fármacos , Receptores de N-Metil-D-Aspartato/administración & dosificación , Cola (estructura animal)/efectos de los fármacos , Cola (estructura animal)/lesiones , Cola (estructura animal)/fisiopatología
7.
J Pharmacol Sci ; 95(4): 476-8, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15297769

RESUMEN

Hot flushes are one of the most frequent symptoms in menopausal women. We investigated effect of soybean isoflavones (Soyaflavone HG) on nifedipine-induced flushing in ovariectomized mice. Ovariectomy markedly aggravated nifedipine-induced increase in tail skin temperature. Soyaflavone HG (10 mg/kg, p.o., once a day for 5 days) inhibited nifedipine-induced flushing in ovariectomized mice. The inhibitory effect of Soyaflavone HG was significantly reversed by an estrogen-receptor antagonist, ICI 182,780, suggesting that Soyaflavone HG prevents nifedipine-induced flushing partially through estrogen receptors. We presented the experimental evidence suggesting that soybean isoflavones including Soyaflavone HG have the benefits for menopausal hot flushes.


Asunto(s)
Estradiol/análogos & derivados , Glycine max , Sofocos/prevención & control , Isoflavonas/uso terapéutico , Animales , Relación Dosis-Respuesta a Droga , Estradiol/uso terapéutico , Antagonistas de Estrógenos/uso terapéutico , Femenino , Fulvestrant , Sofocos/inducido químicamente , Isoflavonas/administración & dosificación , Ratones , Ratones Endogámicos ICR , Nifedipino , Ovariectomía , Fitoterapia , Extractos Vegetales/uso terapéutico , Temperatura Cutánea/efectos de los fármacos , Cola (estructura animal)/fisiopatología , Vasodilatadores
8.
Neurosci Lett ; 319(3): 141-4, 2002 Feb 22.
Artículo en Inglés | MEDLINE | ID: mdl-11834313

RESUMEN

To investigate the involvement of nuclear factor kappa B1 (NF-kappaB1; p50/p105) in electroacupuncture (EA)-induced analgesia, 2 and 100 Hz EA stimulations were applied at acupoint ST36 (Zusanli) in NF-kappaB1 knockout mice. EA was performed for 30 min and tail-flick latencies (TFLs) were evaluated every 15 min for 1 h. Wild-type mice displayed a 63.3% increase in TFLs compared to baseline after 2 Hz EA, whereas NF-kappaB1+/- mice exhibited a 41.8% increase and NF-kappaB1-/- mice showed only a 3.9% increase of TFLs. The TFLs of 100 Hz EA showed similar trends: a 72.6% increase of TFLs in wild-type, a 38.6% increase in NF-kappaB1+/- and a 9.3% increase in NF-kappaB1-/- mice. The present findings suggest that NF-kappaB1 may play a crucial role in both low and high frequency EA-induced analgesic effects.


Asunto(s)
Analgesia , Electroacupuntura , FN-kappa B/fisiología , Animales , Femenino , Masculino , Ratones , Ratones Noqueados/genética , FN-kappa B/genética , Dolor/fisiopatología , Dimensión del Dolor , Isoformas de Proteínas/genética , Isoformas de Proteínas/fisiología , Tiempo de Reacción/fisiología , Cola (estructura animal)/fisiopatología
9.
Neurobiology (Bp) ; 9(1): 17-22, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11558930

RESUMEN

Lateral hypothalamus (LHA) plays a very important role in the modulation of nociceptive behaviour. The stimulation of LHA is known to produce analgesia of both tonic and phasic pain. The present study reports hyperalgesia induced by lateral hypothalamic lesions and the effect of fetal (gestation day 16) hypothalamic transplant on the nociceptive response to phasic thermal noxious stimulation [tail flick latency (TFL)] in LHA lesioned rats. The TFL decreased significantly (12.91 +/- 3.91 sec to 10.51+/- 1.23 sec) following LHA lesion. However, after transplantation, the TFL did not change. This is the first report of a hypothalamic transplant inducing recovery of a nociceptive response.


Asunto(s)
Encefalopatías/complicaciones , Trasplante de Tejido Fetal , Hiperalgesia/etiología , Hiperalgesia/cirugía , Área Hipotalámica Lateral , Hipotálamo/embriología , Animales , Encefalopatías/fisiopatología , Masculino , Actividad Motora , Nociceptores/fisiopatología , Dimensión del Dolor/métodos , Ratas , Ratas Wistar , Tiempo de Reacción , Recuperación de la Función , Cola (estructura animal)/fisiopatología
10.
Jpn J Pharmacol ; 79(3): 387-91, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10230868

RESUMEN

Using streptozotocin-induced diabetic mice and rats, we evaluated the antinociceptive mechanism of Gosha-jinki-gan. The antinociceptive effect of Gosha-jinki-gan (0.3 g/kg, p.o.) in diabetic mice, as determined by the tail-pressure test, was inhibited by N(G)-nitro-L-arginine methyl ester (L-NAME; 2, 5 mg/kg, i.p.). When L-NAME (10 microg) or methylene blue (500 microg) was topically administered to the intraplantar area of the hind paw, the region used for the paw-pressure test, the antinociceptive activity of Gosha-jinki-gan (0.3 g/kg, p.o.) in diabetic rats was decreased. These results suggested that the antinociceptive effect of Gosha-jinki-gan partly resulted from the peripheral action of increasingly produced nitric oxide.


Asunto(s)
Analgésicos/farmacología , Diabetes Mellitus Experimental/fisiopatología , Medicamentos Herbarios Chinos/farmacología , Dolor/prevención & control , Animales , Arginina/farmacología , Inhibidores Enzimáticos/farmacología , Masculino , Azul de Metileno/farmacología , Ratones , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico/fisiología , Nociceptores/efectos de los fármacos , Dolor/fisiopatología , Umbral del Dolor/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Cola (estructura animal)/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA